Skip to main content
SpringerLink
Log in

Special Issues Concerning Postmenopausal Hormone Replacement Therapy and Breast Cancer

  • Chapter
Comprehensive Management of Menopause

Part of the book series: Clinical Perspectives in Obstetrics and Gynecology ((CPOG))

  • 91 Accesses

Abstract

Over the past decade there have been several studies that have suggested that long-term use of hormone replacement therapy (HRT) with estrogens by postmenopausal women, may improve overall life expectancy.1–4 This is due largely to dramatic reductions in risk of cardiovascular risk. Other favorable effects have been noted such as a reduction in osteoporosis. Thus there continues to be a strong interest in taking HRT and a stronger rationale for taking them on a long-term basis, and not merely for a brief period for climacteric symptoms.5

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Criqui MH, Suarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality. Am J Epidemiol 1988; 128: 606–614.

    PubMed  CAS  Google Scholar 

  2. Petitti DB, Perlman JA, and Sidney S. Non-contraceptive estrogens and mortality: Longterm follow-up of women in the Walnut Creek Study. Obstet and Gyne. 1987; 70: 289–293.

    CAS  Google Scholar 

  3. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med. 1991; 151: 75–78.

    Article  PubMed  CAS  Google Scholar 

  4. Hunt K, Vessey M, McPherson K, and Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gyne. 1987; 94: 620–635.

    Article  CAS  Google Scholar 

  5. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B. Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992; 1038–1041.

    Google Scholar 

  6. Bush TL, Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature. In Korenman SG ed. the Menopause. Biological and Clinical Consequences of Ovarian Failure: Evolution and Management. Norwell, Mass; Sereno Symposia; 1990: 211–223.

    Google Scholar 

  7. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prey Med. 1991; 20: 47–63.

    Article  CAS  Google Scholar 

  8. Jensen J, Nilas I, Christiansen C. Influence of menopause on serum lipids and lipoproteins. 1988; 10: 271–282.

    Google Scholar 

  9. Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. N Engl J Med 1985; 313: 1038–1043.

    Article  PubMed  CAS  Google Scholar 

  10. Gambrell RD. Use of progestogens in postmenopausal women. Int J Fertil. 1989; 34: 315–321.

    PubMed  Google Scholar 

  11. Gambrell RD. Use of progestogens in postmenopausal women. Int J Fertil. 1989; 34: 315–321.

    PubMed  Google Scholar 

  12. Love RR, Newcombe PA, Wiebe DA. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with nodenegative breast cancer. J Natl Cancer 1. 1990; 82: 1327–1332.

    Article  Google Scholar 

  13. Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339: 1–15, 71–85.

    Google Scholar 

  14. Weiss NS, Ure CL, Ballard JH, et al. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980; 303: 1195–8.

    Article  PubMed  CAS  Google Scholar 

  15. Ettinger B, Genant KH, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985; 102: 319–24.

    PubMed  CAS  Google Scholar 

  16. Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least 2 years. Breast Cancer Res Treat. 1988; 12: 297–302.

    Article  PubMed  CAS  Google Scholar 

  17. Henderson BE. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol 1989; 161: 1859–1864.

    PubMed  CAS  Google Scholar 

  18. Shapiro S, Kelly JP, Rosenberg L, Kaaufman DW, Helmrich SP, Rosenshein NB, Lewis JL, Knapp RC, Stolley PD, Schottenfeld D. Risk of localized and wisespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985; 313: 969–972.

    Article  PubMed  CAS  Google Scholar 

  19. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy. Am J Obstet Gynecol 1979; 133: 537–547.

    PubMed  CAS  Google Scholar 

  20. Ettinger B, Golditch IM, Friedman G. Gynecologic consequences of long-term unopposed estrogen replacement therapy. Maturitas Maturitas 1990; 12: 321–331.

    Google Scholar 

  21. Voigt LF, Weiss NS, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991; 338: 274–277.

    Article  PubMed  CAS  Google Scholar 

  22. Paganini-Hill A, Ross RK, Henderson BE.Endometrial cancer and patterns of use of oestrogen replacement therapy: A cohort study. Br J Cancer 1989; 59: 445–447.

    Article  PubMed  CAS  Google Scholar 

  23. Persson I, Adami H-O, Bergkvist L, Lindgren A, Pettersson B, Hoover R, Schairer C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: Results of a prospective study. Br Med J. 1989, 298: 147–154.

    Article  CAS  Google Scholar 

  24. NSABP Protocol P-1. A clinical trial to determine the worth of tamoxifen for preventing breast cancer. NSABP Pittsburgh, PA.

    Google Scholar 

  25. Armstrong BK. Oestrogen therapy after menopause—boon or bane? Med J Aust. 1988; 148: 213–214.

    PubMed  CAS  Google Scholar 

  26. Dupont WD, and Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Int Med. 1991; 151: 67–72.

    Article  CAS  Google Scholar 

  27. Dupont WD, Page DL, Rogers LW, and Parl FF. Influence of exogenous estrogens, proliferative disease, and other variables on breast cancer risk. Cancer 1989. 63: 948–957.

    Article  PubMed  CAS  Google Scholar 

  28. Steinberg KK, Thacker SB, Smith J, Stroup DF, Zack; MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. 1991: 265: 1985–1990.

    CAS  Google Scholar 

  29. Gail MH, Brinton LA, Byar DP, Green SB, Schairer C, and Mulvihill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989; 81: 1879–1886.

    Article  PubMed  CAS  Google Scholar 

  30. Carter CL, Allen C, and Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989; 63: 181–187.

    Article  PubMed  CAS  Google Scholar 

  31. Creasman WT, Estrogen replacement therapy: is previously treated cancer a contraindication. Obstet Gynecol. 1991: 77: 308–312.

    Article  PubMed  CAS  Google Scholar 

  32. Theriault RL, Sellin RV. A clinical delemma: Estrogen replacement therapy in postmenopausal women with a background of primary breast cancer. Ann Oncol. 1991; 2: 709–717.

    Google Scholar 

  33. Nachtigall LE, Nachtigall RH, Nachtigall RD, and Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular disease and metabolic problems. Obstet Gynecol. 1979; 54: 74–79.

    Article  PubMed  CAS  Google Scholar 

  34. Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293–297.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Peter M. Ravdin
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Obstetrics and Gynecology, Université de Montréal, Hôpital du Sacré-Coeur de Montréal, H4J 1C5, Montréal, Quebec, Canada

    Jacques Lorrain M.D., FRCS(C), FACOG (Clinical Professor, Director) (Clinical Professor, Director)

  2. Gynecological Endocrinology and Reproductive Medicine, Hôpital du Sacré-Coeur de Montréal, H4J 1C5, Montréal, Quebec, Canada

    Jacques Lorrain M.D., FRCS(C), FACOG (Clinical Professor, Director) (Clinical Professor, Director)

  3. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics-Gynecology, Medical College of Georgia, 30912-3360, Augusta, GA, USA

    Leo Plouffe Jr. M.D. (Associate Professor/Director of Clinical Services) (Associate Professor/Director of Clinical Services)

  4. University of Massachusetts Medical Center, 01655, Worcester, MA, USA

    Veronica A. Ravnikar M.D. (Professor of Obstetrics and Gynecology, Director of Reproductive Endocrinology, Fertility, Menopause) (Professor of Obstetrics and Gynecology, Director of Reproductive Endocrinology, Fertility, Menopause)

  5. Division of Reproductive Endocrinology, Department of Obstetrics and Gynecology, Oregon Health Sciences University School of Medicine, 97201-3098, Portland, OR, USA

    Leon Speroff M.D. (Professor and Chairman) (Professor and Chairman)

  6. Division of Endocrinology, Department of Medicine, The Emory University School of Medicine, 30322, Atlanta, GA, USA

    Nelson B. Watts M.D. (Associate Professor) (Associate Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag New York, Inc.

About this chapter

Cite this chapter

Ravdin, P.M. (1994). Special Issues Concerning Postmenopausal Hormone Replacement Therapy and Breast Cancer. In: Lorrain, J., Plouffe, L., Ravnikar, V.A., Speroff, L., Watts, N.B. (eds) Comprehensive Management of Menopause. Clinical Perspectives in Obstetrics and Gynecology. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-4330-4_38

Download citation

  • DOI: https://doi.org/10.1007/978-1-4612-4330-4_38

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4612-8737-7

  • Online ISBN: 978-1-4612-4330-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation